Nektar Therapeutics (NAS: NKTR) is expected to report Q2 earnings on Aug. 9. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nektar Therapeutics' revenue will improve 15.8% and EPS will remain in the red.
The average estimate for revenue is $20.1 million. On the bottom line, the average EPS estimate is -$0.33.
Last quarter, Nektar Therapeutics booked revenue of $17.9 million. GAAP reported sales were 59% higher than the prior-year quarter's $11.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.34. GAAP EPS were -$0.36 for Q1 versus -$0.33 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 51.5%, 1,960 basis points worse than the prior-year quarter. Operating margin was -202.0%, 9,770 basis points better than the prior-year quarter. Net margin was -229.0%, 8,990 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $81.0 million. The average EPS estimate is -$1.42.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 192 members out of 220 rating the stock outperform, and 28 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Nektar Therapeutics a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $11.00.
Over the decades, small-cap stocks like Nektar Therapeutics have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
Add Nektar Therapeutics to My Watchlist.
The article What to Expect From Nektar Therapeutics originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.